(:MNK)

Mar 26, 2024 04:01 pm ET
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Exceeds High End of Guidance Range on Net Sales and Adjusted EBITDA for Fiscal Year
Feb 02, 2024 07:45 am ET
Mallinckrodt Announces Board of Directors and Leadership Updates
Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
Jan 22, 2024 05:52 am ET
Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress
– Oral presentation of a post hoc analysis of the Phase 3 CONFIRM trial details the therapeutic effect of TERLIVAZ in adult patients with hepatorenal syndrome (HRS) and alcoholic hepatitis (AH)1 –
Nov 10, 2023 10:24 am ET
High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement
Company Expects to Complete Irish Examinership and Emerge from Chapter 11 in Coming Days
Nov 01, 2023 06:45 am ET
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting
–Three scientific abstracts via one oral and two poster presentations detail the Company's latest clinical research findings on the therapeutic effect of TERLIVAZ for adults with HRS involving rapid reduction in kidney function1 –
Oct 26, 2023 06:53 am ET
Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023
-- Findings from two health economics analyses of Acthar Gel provide further insight into its cost-effectiveness as a treatment option for advanced symptomatic sarcoidosis,1 and its impact on clinical, economic, and real-world outcomes in patients with nephrotic syndrome2 --
Sep 05, 2023 11:06 am ET
DEADLINE ALERT for BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 01, 2023 12:30 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Sep 01, 2023 10:25 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers. The class action, filed in the United States District Court for the District of New...
Aug 31, 2023 09:15 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 28, 2023 11:13 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 28, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Aug 26, 2023 12:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New...
Aug 25, 2023 10:35 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt”...
Aug 24, 2023 10:05 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 22, 2023 11:11 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 21, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Aug 20, 2023 01:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New...
Aug 17, 2023 12:47 pm ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 15, 2023 11:15 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 14, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Aug 12, 2023 01:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New...
Aug 11, 2023 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt”...
Aug 10, 2023 09:00 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 09, 2023 11:17 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 07, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Aug 03, 2023 05:13 pm ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 02, 2023 03:43 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt”...
Aug 02, 2023 12:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers. The class action, filed in the United States District Court for the District of New...
Aug 02, 2023 11:15 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 01, 2023 09:35 am ET
MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit
BENSALEM, Pa., Aug. 1, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK).
Jul 31, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Jul 29, 2023 08:00 am ET
MALLINCKRODT SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their
NEW YORK, July 29, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jul 28, 2023 11:07 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 28, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt”...
Jul 27, 2023 11:55 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New...
Jul 27, 2023 10:30 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 25, 2023 01:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-03662, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defe
Jul 25, 2023 11:06 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Jul 24, 2023 10:06 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Law Offices of Howard G. Smith reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”).
Jul 24, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Jul 22, 2023 08:00 am ET
MALLINCKRODT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Opti
NEW YORK, July 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jul 21, 2023 12:50 pm ET
DEADLINE ALERT for BTAI, MNK, STX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 21, 2023 11:09 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Jul 20, 2023 11:08 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 20, 2023 10:34 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Jul 20, 2023 09:06 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”). Mallinckrodt investors have until September 5, 2023 to file a lead pla
Jul 19, 2023 12:34 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Jul 19, 2023 11:56 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New...
Jul 19, 2023 10:06 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) investors concerning the Company’s possible violations of federal securities laws.
Jul 17, 2023 01:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
NEW YORK, July 17, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK), and certain officers.  The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-03662, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defen
Jul 17, 2023 09:00 am ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its...
Jul 15, 2023 08:00 am ET
MALLINCKRODT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Opti
NEW YORK, July 15, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jul 14, 2023 04:49 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Jul 13, 2023 06:00 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors with Over $1 Million in Losses to Secure Counsel Before Important Deadline in Securities Class Action – MNK, MNKPF
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Mallinckrodt plc (NYSE American: MNK) (OTC: MNKPF) between June 17, 2022 and June 14, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2023.
Jul 13, 2023 03:13 pm ET
Mallinckrodt plc investors: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline
The Portnoy Law Firm advises Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSEAM: MNK) investors that a lawsuit filed on behalf of investors that purchased Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive...
Jul 13, 2023 12:43 pm ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its officers.
Jul 12, 2023 12:42 pm ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSEAM: MNK) and certain of its officers.
Jul 11, 2023 04:00 pm ET
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
NEW YORK, July 11, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and certain of its officers.
Jul 09, 2023 11:32 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK), and certain officers. The class action, filed in the United States District Court for the District of New...
Jun 15, 2023 06:52 am ET
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023
– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ® from baseline, and the clinical management of adults with HRS with rapid reduction in kidney function1 –
Jun 01, 2023 06:52 am ET
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023
– Findings from two clinical studies in adults with HRS involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3 –
May 09, 2023 06:45 am ET
Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance
Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest
May 08, 2023 06:52 am ET
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023
– Findings from two clinical study presentations in adults with HRS involving rapid reduction in kidney function1 provide insight into the appropriate use of terlipressin for the care of critically ill patients2,3 –
May 05, 2023 06:52 am ET
Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards
– TERLIVAZ® (terlipressin) is the only FDA approved treatment for adults with HRS with rapid reduction in kidney function1 –
Apr 28, 2023 08:00 am ET
Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment Scheme
The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company’s Board of Directors, given their failure to provide any response to BHG’s March 17, 2023, open letter, which extensively outlaid – after extensive investigation – an evidential multibillion-dollar scheme of concealing asset value depreciation expenses from the Company’s pre- and post-reorganization fina
Apr 24, 2023 06:45 am ET
Mallinckrodt to Report Earnings Results for First Quarter 2023
DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023. 
Apr 16, 2023 07:00 pm ET
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK
NEW YORK, April 16, 2023 /PRNewswire/ --
Apr 13, 2023 06:00 pm ET
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK
NEW YORK, April 13, 2023 /PRNewswire/ --
Apr 10, 2023 06:53 am ET
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)
– Two scientific abstracts spanning clinical and health economic outcomes research will be presented at the 2023 NKF SCM, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function[1] –
Apr 09, 2023 01:29 pm ET
MNK LOSS ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation – MNK
WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially...
Apr 09, 2023 02:54 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK
Pomerantz LLP is investigating claims on behalf of investors of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 07, 2023 02:52 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK
NEW YORK, April 7, 2023 /PRNewswire/ --
Apr 03, 2023 12:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK
NEW YORK, April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 31, 2023 06:31 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation – MNK
WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially...
Mar 27, 2023 07:26 pm ET
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK
NEW YORK, March 27, 2023 /PRNewswire/ -- 
Mar 22, 2023 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK
NEW YORK, March 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 21, 2023 08:58 pm ET
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK
NEW YORK, March 21, 2023 /PRNewswire/ --
Mar 21, 2023 10:45 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE American:
Mar 21, 2023 06:53 am ET
Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed
– Findings from a retrospective analysis suggest that treatment with Acthar Gel is associated with significant reductions in corticosteroid use compared to other fourth-line alternatives for patients with advanced sarcoidosis1 –
Mar 20, 2023 03:46 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE American:
Mar 20, 2023 10:14 am ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation – MNK
WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public.
Feb 16, 2023 07:03 am ET
Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference
DUBLIN, Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time.
Feb 08, 2023 05:45 am ET
Mallinckrodt to Report Earnings Results for Fourth Quarter 2022
DUBLIN, Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023. 
Jan 22, 2023 01:00 pm ET
Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress
– Findings from a retrospective analysis suggest that patients with baseline acute-on-chronic liver failure (ACLF) grade ≤2 treated with TERLIVAZ® plus albumin had a higher incidence of HRS reversal than those treated with placebo plus albumin1 –
Jan 12, 2023 05:45 am ET
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He
Nov 08, 2022 05:45 am ET
Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance
Launched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax®
Nov 03, 2022 06:53 am ET
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver
– Seven scientific abstracts spanning clinical and health economic outcomes research will be presented at the AASLD Liver Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function1 –
Nov 01, 2022 06:53 am ET
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting
– Three scientific abstracts highlighting clinical research of terlipressin treatment for adults with HRS involving rapid reduction in kidney function1 will be presented at the ASN Scientific Meeting, reinforcing Mallinckrodt's ongoing commitment to critically ill patients –
Oct 24, 2022 06:45 am ET
Mallinckrodt Receives Approval to List on NYSE American
Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022
Oct 06, 2022 06:45 am ET
Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors
DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022. With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent.
Sep 14, 2022 10:14 pm ET
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)
– Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function1 –
Jun 23, 2022 06:52 am ET
Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress
-Post-hoc analyses showcase Mallinckrodt's commitment to patients with HRS involving rapid reduction in kidney function,1an acute and life-threatening condition2-
Mar 28, 2022 06:45 am ET
Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context
– Electronic medical chart analysis showed Acthar Gel was associated with clinical improvements and a reduction in prescriptions for concomitant medications in refractory rheumatoid arthritis patients –
Jun 15, 2021 07:15 pm ET
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)
DUBLIN, June 15, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). Please see Important Safety Information for StrataGraft below.
Oct 29, 2020 06:35 am ET
Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated wi
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Results were presented at Kidney Week 2020 Reimagined, the annual meeting of the American Society of Nephrology. The results, based on pooled analyses of three Phase 3 trials including the pivotal CONFIRM study, found that HRS-1 patients treated with terli
Aug 04, 2020 06:00 am ET
Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements
DUBLIN, Aug. 4, 2020 /PRNewswire/ --
Jul 15, 2020 06:12 pm ET
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)
DUBLIN, July 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1) (8 yes; 7 no). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Terlipressin is an investigational agent being evaluated for the treatment of HRS-1 in the U.S., and its safety and effecti
Jul 09, 2020 06:45 am ET
Mallinckrodt to Report Earnings Results for Second Quarter 2020
STAINES-UPON-THAMES, United Kingdom, July 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earnings results for the period ended June 26, 2020 on Tuesday, Aug. 4, 2020. 
Jul 07, 2020 09:26 am ET
Mallinckrodt Confirms that U.S. Food and Drug Administration (FDA) Will Convene an Advisory Committee to Review Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
STAINES-UPON-THAMES, United Kingdom, July 7, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will, as expected, hold a virtual meeting to review data on terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). The company announced the FDA accepted for review its New Drug Application (NDA) for terlipressin in April. 
Jun 17, 2020 06:45 am ET
Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference
STAINES-UPON-THAMES, United Kingdom, June 17, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors.  A replay of the fireside chat will also be avail
Jun 15, 2020 10:50 am ET
Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services
STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the U.S. Court of Appeals for the District of Columbia decision to deny its request for a temporary injunction preventing the U.S. Centers for Medicare and Medicaid Services (CMS) from enforcing a change in Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection). Mallinckrodt had asked for the temporary injunction as it appeals a lower court ruling that allowed CMS to reset the base date average ma
Jun 15, 2020 06:30 am ET
Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting
STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 clinical trial (STRATA2016) of its investigational product StrataGraft®, a regenerative skin tissue therapy in development for the treatment of deep partial-thickness thermal burns, as well as health economics and outcomes research (HEOR) and other data on the treatment of burns as part of the virtual American Burn Association (ABA) 52nd Annual Meeting. The virtual meeting begins today and is accessi
Jun 11, 2020 06:45 am ET
Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics
STAINES-UPON-THAMES, United Kingdom, June 11, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type 1 (HRS-1), an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 The study, funded by Mallinckrodt, found that terlipressin was associated with an improvement in kidney function among HRS-1 patients as measured by a reduction in se
Jun 09, 2020 06:32 am ET
Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration
STAINES-UPON-THAMES, United Kingdom, June 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for StrataGraft®, a regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The company previously announced initiation of the rolling submission in April. StrataGraft skin tissue is an investigational product, an
Jun 01, 2020 06:45 am ET
Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)
STAINES-UPON-THAMES, United Kingdom, June 1, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. District Court for the District of Columbia in a lawsuit filed by its subsidiary, Mallinckrodt ARD LLC, against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS), regarding the Medicaid drug rebate calculation for Acthar® Gel (repository corticotropin injection).
May 05, 2020 06:45 am ET
Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline Progress
STAINES-UPON-THAMES, United Kingdom, May 5, 2020 /PRNewswire/ --
May 04, 2020 06:45 am ET
Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 Observational Registry in Neonates with Pulmonary Hypertension; Ends Trial Early
STAINES-UPON-THAMES, United Kingdom, May 4, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety and effectiveness of INOmax® (nitric oxide) gas, for inhalation, in term and near-term neonates to that in preterm neonates with pulmonary hypertension (PH) was ended early due to achievement of the pre-specified primary outcome measure, non-inferiority (95 percent confidence interval: -0.0021, 0.1158, with a pre-defined margin of -0.1452). The decision was made following the second planned inte
Apr 30, 2020 08:04 am ET
Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to
STAINES-UPON-THAMES, United Kingdom, April 30, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at Massachusetts General Hospital evaluating the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19. Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
Apr 22, 2020 06:45 am ET
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)
STAINES-UPON-THAMES, United Kingdom, April 22, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). On March 17, 2020 the company announced the completion of its rolling submission of the NDA for terlipressin. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of September 12, 2020.
Apr 16, 2020 06:45 am ET
Mallinckrodt to Report Earnings Results for First Quarter 2020
STAINES-UPON-THAMES, United Kingdom, April 16, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report first quarter 2020 earnings results for the period ended March 27, 2020 on Tuesday, May 5, 2020. 
Apr 15, 2020 06:45 am ET
Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheum
STAINES-UPON-THAMES, United Kingdom, April 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the publication of findings from its randomized, placebo-controlled, double-blind Phase 4 study to assess the safety and efficacy of Acthar® Gel (repository corticotropin injection, or RCI) in patients with persistently active rheumatoid arthritis (RA) despite treatment with stable background disease-modifying antirheumatic drugs (DMARDs) and low-dose glucocorticoids. Results of the study were recently published online in Rheumatology and Thera
Apr 06, 2020 06:45 am ET
Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration
STAINES-UPON-THAMES, United Kingdom, April 6, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval to market StrataGraft®, a regenerative skin tissue therapy, for the treatment of adult patients with deep partial-thickness thermal burns. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been establ
Apr 01, 2020 06:45 am ET
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications
-- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 --
Apr 01, 2020 06:45 am ET
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications
-- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 --
Mar 17, 2020 06:45 am ET
Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
STAINES-UPON-THAMES, United Kingdom, March 17, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 (HRS-1). The company previously announced the rolling submission, which it initiated in February. 
Mar 16, 2020 06:00 am ET
Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Op
STAINES-UPON-THAMES, United Kingdom, March 16, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed that its subsidiary, Mallinckrodt ARD LLC, received a decision from the U.S. District Court for the District of Columbia in its suit against HHS and CMS (or the Agency) regarding the company's calculation of Medicaid drug rebates for Acthar® Gel (repository corticotropin injection). The District Court upheld CMS' decision to reverse its previous determination of the base date average manufacturer price (AMP) used to calculate Acthar Gel rebates
Nov 12, 2019 03:30 pm ET
Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatolo
STAINES-UPON-THAMES, United Kingdom, Nov. 12, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced data on patient-reported outcomes (PROs) showing Acthar® Gel (repository corticotropin injection) improved disease measures that impact rheumatoid arthritis (RA) patients with persistently active disease, as well as new data from an exploratory analysis. The data originate from new analyses from Mallinckrodt's Phase 4 study of Acthar Gel in RA patients with persistently active disease and was recently presented at the 2019 American College of Rh
Nov 11, 2019 02:30 pm ET
Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019
STAINES-UPON-THAMES, United Kingdom, Nov. 11, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safety of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Results were reported during a late-breaking abstract presentation today at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liv
Nov 08, 2019 05:45 am ET
Mallinckrodt to Present at Jefferies London Healthcare Conference
STAINES-UPON-THAMES, United Kingdom, Nov. 8, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday, Nov. 20, 2019.
Nov 07, 2019 05:45 am ET
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population
STAINES-UPON-THAMES, United Kingdom, Nov. 7, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the publication of "Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population" in an electronic publication posted in advance of print publication in the peer-reviewed journal Neurology and Therapy. Results from the analysis showed that multiple sclerosis (MS) relapse patients taking Acthar® Gel (repository corticotropin injection) had a higher relapse resolution rate than those taking intravenous immun
Nov 05, 2019 05:05 am ET
Mallinckrodt plc Announces Exchange Offers and Consent Solicitations
STAINES-UPON-THAMES, United Kingdom, Nov. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced the commencement of private offers (each, an "Exchange Offer" and, collectively, the "Exchange Offers") by its wholly owned subsidiaries, Mallinckrodt International Finance S.A. and Mallinckrodt CB LLC (the "Issuers") to exchange:
Nov 05, 2019 05:00 am ET
Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019
STAINES-UPON-THAMES, United Kingdom, Nov. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the three months ended September 27, 2019. Unless otherwise noted, the quarter comparisons are to the recast prior year comparable three months ended September 28, 2018.
Nov 04, 2019 03:30 pm ET
Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 Million
STAINES-UPON-THAMES, United Kingdom, Nov. 4, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it has completed the sale of its wholly owned subsidiary BioVectra Inc. to an affiliate of H.I.G. Capital, a leading global private equity investment firm.
Oct 31, 2019 04:35 pm ET
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifesta
STAINES-UPON-THAMES, United Kingdom, Oct. 31, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that UVADEX® (methoxsalen) has received regulatory approval in Australia by the Therapeutic Goods Administration (TGA) for extracorporeal administration with the THERAKOS® CELLEX® Photopheresis System. The treatment is indicated for steroid-refractory and steroid-intolerant chronic graft versus host disease (cGvHD) in adults following allogeneic hematopoietic stem cell (HSC) transplantation. The TGA also approved Uvadex in conjunction with the T
Oct 21, 2019 04:45 pm ET
Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week
STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, is proud to celebrate Respiratory Care Week (October 20-26, 2019), and honor the role of respiratory therapists in providing critical care to patients in respiratory distress.
Oct 21, 2019 10:15 am ET
Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019
STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present results from its pivotal Phase 3 CONFIRM study in a late-breaker session on Monday, Nov. 11 at 3:30 pm ET during The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
Oct 09, 2019 06:45 am ET
Mallinckrodt to Report Earnings Results for Third Quarter 2019
STAINES-UPON-THAMES, United Kingdom, Oct. 9, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report third quarter 2019 earnings results for the period ended Sept. 27, 2019 on Tuesday, Nov. 5, 2019. 
Oct 01, 2019 06:45 am ET
Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin I
STAINES-UPON-THAMES, United Kingdom, Oct. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced positive top-line findings from its observational registry to assess treatment patterns and response to Acthar® Gel (repository corticotropin injection) in reducing the clinical impact of disease exacerbations in patients with multiple sclerosis (MS) relapse. The results for the main subsets of patients are highly statistically significant for all the efficacy endpoints. Mallinckrodt plans to share the data at an upcoming medical meeting.
Sep 30, 2019 06:49 am ET
Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit
STAINES-UPON-THAMES, United Kingdom, Sept. 30, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), along with its wholly owned subsidiaries Mallinckrodt LLC and SpecGx LLC, today announced that it has executed a definitive settlement agreement and release (the "Settlement Agreement") with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation (MDL) in the U.S. District Court for the Northern District of Ohio: The County of Cuyahoga, et al. v. Purdue Pharma, L.P., et al., Case No. 17-OP-45004; and The County of Summit, et al. v. Purdue Pharm
Sep 24, 2019 01:17 pm ET
MALLINCKRODT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company")  of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Sep 24, 2019 08:47 am ET
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE:
Sep 23, 2019 03:00 pm ET
SHAREHOLDER ALERT - Mallinckrodt plc (MNK) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: September 24, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt”  or the Company”) (NYSE: MNK) and certain of its officers, on behalf of shareholders...
Sep 23, 2019 09:27 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LB, MNK, JE and PS
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 23, 2019 09:15 am ET
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 23, 2019 06:45 am ET
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
STAINES-UPON-THAMES, United Kingdom, Sept. 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced positive top-line results from its pivotal Phase 3 clinical trial of its investigational StrataGraft® regenerative tissue. The study, which met both primary endpoints, evaluated the efficacy and safety of a single application of StrataGraft in the treatment of deep partial-thickness thermal burns. Each study participant served as his or her own control.
Sep 21, 2019 10:00 am ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Mallinckrodt Plc (NYSE: MNK) and Encourages Mallinckrodt Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Mallinckrodt Plc (NYSE: MNK) securities between February 28, 2018 and July 16, 2019 (the “Class Period”). Investors have until September 24, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 20, 2019 11:30 am ET
GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Mallinckrodt plc Investors of Important Deadline in Securities Class Action – MNK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”) of the important September 24, 2019 lead plaintiff...
Sep 20, 2019 06:45 am ET
Mallinckrodt to Present at Cantor Global Healthcare Conference
STAINES-UPON-THAMES, United Kingdom, Sept. 20, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the InterContinental New York Barclay, 111 E. 48th St., New York on Wednesday, Oct. 2, 2019.
Sep 19, 2019 01:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its officers. The class action, filed in United States District Court, for the Southern...
Sep 19, 2019 11:19 am ET
CLASS ACTION UPDATE for NFLX, MNK and OLLI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 19, 2019 10:00 am ET
FINAL DEADLINE ALERT - Mallinckrodt plc (MNK) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: September 24, 2019
NEW YORK, Sept. 19, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt"  or the Company") (NYSE: MNK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mallinckrodt securities between February 28, 2018 and July 16, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/mnk.
Sep 18, 2019 08:14 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Mallinckrodt Plc (NYSE: MNK) and Encourages Mallinckrodt Investors to Contact the Firm
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Mallinckrodt Plc (NYSE: MNK) securities between February 28, 2018 and July 16, 2019 (the "Class Period").  Investors have until September 24, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 17, 2019 01:30 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) investors who...
Sep 17, 2019 10:30 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Law Offices of Howard G. Smith reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”)...
Sep 17, 2019 10:02 am ET
CLASS ACTION UPDATE for MNK, CAH, GVA and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 17, 2019 08:25 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 16, 2019 10:15 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Sep 13, 2019 03:00 pm ET
Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 13, 2019 06:45 am ET
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
STAINES-UPON-THAMES, United Kingdom, Sept. 13, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced findings from a retrospective analysis of Acthar® Gel (repository corticotropin injection) that showed the cost per response of Acthar Gel when used as a late-line treatment was lower than other late-line treatments, including plasmapheresis (PMP) and intravenous immunoglobulin (IVIg), for multiple sclerosis (MS) relapses in adults. In the analysis, response was defined as no additional relapse treatments or procedures within 30 days, and cost
Sep 12, 2019 05:50 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Mallinckrodt plc Investors of Important Deadline in Securities Class Action – MNK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”) of the important September 24, 2019 lead plaintiff...
Sep 12, 2019 02:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:  MNK) and certain of its officers.   The class action, filed in United States District Court, for the Southern...
Sep 10, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investor
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and...
Sep 10, 2019 11:28 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Sep 10, 2019 06:45 am ET
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
STAINES-UPON-THAMES, United Kingdom and MIAMI, Sept. 10, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc. to an affiliate of H.I.G. Capital, a leading global private equity investment firm, for approximately $250 million, including fixed consideration of $175 million, comprised of an upfront payment of $135 million and a long-term note for $40 million, and contingent payments of up to $75 million, enabling Mallinckrodt to capture future BioVectra
Sep 09, 2019 10:20 am ET
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 06, 2019 06:00 pm ET
S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, September 23 to coincide with the September rebalance.
Sep 06, 2019 12:20 pm ET
Mallinckrodt Announces Settlement in Principle to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit
STAINES-UPON-THAMES, United Kingdom, Sept. 6, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), along with its wholly owned subsidiaries Mallinckrodt LLC and SpecGx LLC, today announced that it has reached a settlement in principle with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation (MDL) in the U.S. District Court for the Northern District of Ohio: The County of Cuyahoga, et al. v. Purdue Pharma, L.P., et al., Case No. 17-OP-45004; and The County of Summit, et al. v. Purdue Pharma, L.P., et al., Case No. 18-OP-45090 (collectively
Sep 06, 2019 11:05 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
New York, New York--(Newsfile Corp. - September 6, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Sep 06, 2019 09:27 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, MNK and CAH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Sep 05, 2019 06:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Mallinckrodt plc Investors of Important September 24th Deadline in Securities Class Action – MNK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”) of the important September 24, 2019 lead plaintiff...
Sep 05, 2019 02:39 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its officers.   The class action, filed in United States District Court, for the Southern...
Sep 05, 2019 10:20 am ET
SHAREHOLDER ALERT: RBGLY MNK PS EVH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 04, 2019 11:52 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Sep 04, 2019 03:00 pm ET
NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 04, 2019 09:28 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, NGHC, MNK and EVH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 03, 2019 11:16 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
New York, New York--(Newsfile Corp. - September 3, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Sep 03, 2019 10:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Co
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Carbonite,...
Sep 03, 2019 06:08 pm ET
Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities
STAINES-UPON-THAMES, United Kingdom, Sept. 3, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported the company has finalized a previously disclosed agreement with the U.S. Department of Justice to resolve a civil False Claims Act investigation of Questcor's legacy sales and marketing activities first filed in 2012. Questcor was acquired by Mallinckrodt in August of 2014. Under the settlement, Mallinckrodt has agreed to pay the expected $15.4 million relating to these legacy Questcor activities. Importantly, the settlement agreement contains no
Sep 03, 2019 09:48 am ET
CLASS ACTION UPDATE for VNTR, RBGLY, MNK and VAL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 03, 2019 08:53 am ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Aug 30, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 29, 2019 12:46 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:  MNK) and certain of its officers.   The class action, filed in United States District Court, for the Southern...
Aug 28, 2019 02:43 pm ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
Aug 27, 2019 05:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) investors who...
Aug 27, 2019 02:09 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Law Offices of Howard G. Smith reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”)...
Aug 27, 2019 09:58 am ET
CLASS ACTION UPDATE for OMCL, MNK, PS and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Karyopharm, L Brands, National General, and Mallinckrodt and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), L Brands, Inc. (NYSE: LB), National General Holdings Corp. (NASDAQ: NGHC), and...
Aug 26, 2019 10:01 pm ET
Zhang Investor Law Reminds Investors of Sept. 24 Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK
New York, N.Y., August 26, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class...
Aug 26, 2019 12:15 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Aug 24, 2019 09:39 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:  MNK) and certain of its officers.  The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-07030, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Mallinckrodt securities between February 28, 2018 and July 16, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violation
Aug 24, 2019 09:39 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:  MNK) and certain of its officers.  The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-07030, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Mallinckrodt securities between February 28, 2018 and July 16, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' vi
Aug 23, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) – Class Action Reminder – Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 21, 2019 10:16 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Aug 21, 2019 06:55 am ET
Mallinckrodt to Present at Morgan Stanley 17th Annual Global Healthcare Conference
STAINES-UPON-THAMES, United Kingdom, Aug. 21, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Sept. 10, 2019, at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt, 109 E. 42nd St., New York. 
Aug 20, 2019 03:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:  MNK) and certain of its officers.   The class action, filed in United States District Court, for the Southern...
Aug 20, 2019 10:15 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...
Aug 18, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Con
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Curaleaf...
Aug 16, 2019 02:52 pm ET
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...
Aug 16, 2019 09:33 am ET
SHAREHOLDER ALERT: PVTL FRED EGBN MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 15, 2019 07:15 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Mallinckrodt plc Investors of Important Deadline in Securities Class Action – MNK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the “Class Period”) of the important September 24, 2019 lead plaintiff...
Aug 15, 2019 04:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its officers. The class action, filed in United States District Court, for the Southern...
Aug 15, 2019 12:42 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE:
Aug 15, 2019 10:19 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
New York, New York--(Newsfile Corp. - August 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Mallinckrodt stock or options between February 28, 2018 and July 16, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/MNK. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. CONTACT:FARUQI & FARUQI, LLP685 Third Avenue, 26th FloorNew York, NY 10017Attn: Richard Gonnello, [email protected]: (877) 247-4292 or (212) 983-9330 The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Mallinckrodt Avalanche securities between February 28, 2018 and July 16, 2019 (the "Class Period"). The case, Strougo v. Mallinckrodt Public Limited Company, No. 1:19-cv-07030 was filed on July 26, 2019. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making materially false and/or misleading statements and/or failing to disclose that: (1) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (2) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. Specifically, on July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial, assessing Acthar's safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided "to halt the trial after careful consideration of a recent recommendation by the study's independent Data and Safety Monitoring Board" ("DSMB"), which "was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo" and that "the board also mentioned other adverse events specific to this patient population." On this news, Mallinckrodt's stock price fell from $8.20 on July 16, 2019 to $7.56 on July 17, 2019-a $0.64 or a 7.80% drop. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate an
Aug 15, 2019 09:18 am ET
CLASS ACTION UPDATE for MNK, JE, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 15, 2019 06:45 am ET
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
STAINES-UPON-THAMES, United Kingdom, Aug. 15, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1). The study met its primary endpoint of verified HRS-1 reversal (p=0.012). Verified HRS-1 reversal includes three components: renal function improvement, avoidance of dialysis and short-term survival. The company plans to present the data at an upcoming medical meeting.
Aug 14, 2019 12:43 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
Law Offices of Howard G. Smith reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between February 28, 2018 and July 16, 2019, inclusive (the “Class Period”
Aug 14, 2019 09:49 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INS, CTST, MNK and EVH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 13, 2019 05:00 pm ET
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns
STAINES-UPON-THAMES, United Kingdom, Aug. 13, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft®, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries (ISBI). Study data showed that treatment with a single application of StrataGraft tissue resulted in wound closure by three months in 27 of 29 study participants. None of these 27 study participants required the harvest of donor skin (autograft) by 28 days afte
Aug 13, 2019 09:15 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More